A year earlier, Retrasib reported net profit of RON3.6 million.
Retrasib said total revenue fell 18% on the year to RON29.1 million in January through September, while overall costs decreased 11% to RON28 million.
Sales declined 24% to RON27.1 million.
Retrasib is 80.25%-owned by brothers Octavian and Calin Buzoianu.
Thursday, Retrasib closed up 6.67% at RON0.24 a share in Bucharest. (EUR1=RON4.3288)